Good morning.
Futures green, semis leading. TSM +3% in Taiwan after June revenue blew past — NT$442.7B, up 67.9% YoY, sequential acceleration. Implied move into earnings next week is only 3.6%. That’s too low. Memory (MU, SNDK) getting hit overnight on a KIS spec note, but MLC NAND is already in deficit and SLC substitution is accelerating. Don’t chase the headline.
Asia mixed: TSM lifting Taiwan, but Hynix/Samsung down on that memory noise. China restricting helium exports — tiny output but critical for EUV cooling. Latent risk for the entire semicap chain.
Three themes framing today:
1. TSM is the canary. June revenue inflects hard — HPC/AI wafer demand pulling logic capacity. Sets up a Q2 beat and raise. (3.6% implied move is a gift.)
2. Memory cycle is morphing. Custom memory (CIM/PIM) reshapes the commodity narrative. Street still treating it as a cyclical hog — that’s the mispricing. Deficit in MLC NAND is structural.
3. Hyperscaler capex revision cycle is alive. META just bumped Louisiana campus to 5GW / $50B+ from $27B. MS is now modeling $1.2T/$1.4T for '27/'28. The up-and-right move continues.
4. NVDA vs ASIC parity narrows. NVIDIA pricing density at near ASIC cost per FLOP. Means the TCO argument for custom silicon shrinks to software lock-in and supply security. Labs diversify in absolute terms but still increase NVDA spend.
We'll hit up TSM, MU, META first, then get to semis and networking.
Verdict: The AI infra memo is the story. CapEx trajectory is now the axis the stock trades on. Bulls say it's a necessary moat-builder. Bears say it's a value destroyer at $145B+ run rate. Both have a point — but the rate of change in spend is startling.
Leaked internal memo dropped midweek. Meta plans to deploy 7GW of compute in 2026, doubling to 14GW in 2027. That puts 2026 spend at $145B — top of April's guided range and up from January's $115-135B. The market initially sold off, then recovered +8% on the week. Why? Because the memo also showed supply chain de-risking: multi-year deals with Samsung (memory), Sandisk (flash), Sumitomo (fiber), and AMD (6GW of Instinct accelerators).
The sleeper detail: Meta's in-house Iris AI accelerator enters production at TSMC in September 2026 after clearing bug validation in six weeks with "no major issues." Benchmark's Zgutowicz (Hold) called it an "unusually clean tape-out" for a program that has "stumbled repeatedly since inception." That's a big deal for margin structure if Iris works at scale.
"The result represents an unusually clean tape-out for the Meta Training & Inference Accelerator program, which has stumbled repeatedly since inception." — Benchmark's Mark Zgutowicz
Wolfe threw up a 2027 CapEx estimate of $220B (vs prior numbers). That's a shock number, but Wolfe kept Outperform. BofA ($835 PT) and Piper ($800 PT, top large-cap pick) both say this spend is required to hold AI leadership. Citizens cut PT from $825 to $800 on the CapEx concern but kept Market Outperform. The crowd is split on magnitudes, not direction.
Bull case: Revenue growth is 26% LTM, gross margins at 82%. The CapEx is front-loaded to dominate inference and training. Iris tape-out suggests Meta may reduce dependence on Nvidia over time. WhatsApp and Business Agents are upcoming catalysts. Piper calls it "top large-cap pick" on growth + valuation.
Bear case: $145-220B of CapEx with no near-term ROI visibility. Instagram engagement is decelerating (U.S. time spent +9% vs prior +double-digit streak). Tougher comps ahead. The AI agent thesis has been delayed (Zuckerberg admitted it). Benchmark sits on Hold, effectively saying "too expensive to chase, too risky to short."
Citizens flagged the deceleration: Global time spent +13% YoY in June — 13th consecutive month of double-digit growth. But U.S. time spent +9% broke a 14-month double-digit streak. Global comps get harder from here (June started the tough compares). MAU growth is +3% global, -1% U.S., meaning usage gains are coming from depth, not new users. That's fine — engagement monetization is Meta's wheelhouse — but the rate of change is negative. Something to watch in Q3 prints.
Bottom line: META is pricing in a lot of CapEx optimism. The infra memo clarifies the scale, not the return. If Iris works and agents launch, $800+ is table stakes. If the spend becomes a black hole, the stock has room to compress. Right now the narrative is "necessary investment" — but narratives flip. Position accordingly.
Verdict: RBRK is getting a growth premium bid that isn't fully priced in yet. The Street is waking up to the identity narrative as a durable second act beyond backup. 13 firms have collectively boosted PTs into the $90-110 range from a prior $87-95 cluster. The re-rating has room to run.
Revenue +46% to $1.42B with 81% gross margins. Not bad for a company that's still unprofitable on a GAAP basis (but analysts expect breakeven this year). The headline catalyst this week was the £375M ($500M) UK expansion commitment and naming London as EMEA HQ. That's real capital deployment, not a press release.
Cantor Fitzgerald reiterated Overweight at $95, calling the UK move "a positive indicator for backup and resilience vendors with EU-hosted offerings." The sovereignty angle matters — budget dollars are flowing to vendors with local infrastructure, and RBRK just planted a flag.
BMO raised to $98 from $87, keeping Outperform. Their thesis: Identity solutions are the hidden growth vector. Identity Recovery has been live for six quarters, Identity Resilience for three. Both are gaining traction with new and existing customers.
Bull: Identity resilience is largely complementary to existing security providers (Palo Alto, CrowdStrike) and is replacing point solutions like Semperis. This is a platform expansion story, not a niche backup vendor. Net new ARR came in at $103M vs $85.5M consensus — that's a 20% beat. Growth is accelerating, not decelerating.
Bear: RBRK trades at a massive multiple to forward revenue (north of 10x). The profitability inflection is still ahead of us. If macro tightens and enterprise IT budgets get squeezed, backup/cyber resilience is not immune. The Street could punish this name hard on any ARR miss.
BMO on the competitive moat:
"Rubrik's identity recovery solutions are largely complementary to identity security providers' capabilities at this time, though the firm believes Rubrik is replacing Semperis."
That's the bull case in a nutshell — they're eating a specific competitor's lunch while not stepping on the toes of the platform vendors. Clean wedge strategy.
Trading at the edge of fair value, waiting for a catalyst. Both UBS and Cantor Fitzgerald slapped a $35 price target on GTLB with Neutral ratings — stock is basically right there ($32-33 range). This is a show-me story, and the data points are incremental but not decisive.
UBS hosted management in SF and came away feeling "better" about near-term demand. The line that jumps out: seat growth described as "very healthy." That’s the bull case in a nutshell — stabilization of the core business after a messy Q1 print where macro, tech layoffs, and reorgs spooked the Street.
"Management commentary around strength in seat growth, described as 'very healthy,' stood out as the most positive datapoint." — UBS analyst Radi Sultan
Cantor’s take is incrementally positive on new logo momentum — Q1 FY27 new logos +30% YoY, and QTD Q2 first orders up ~100%. But the consumption run rate revision (from ~$20M on the call to ~$15M after refining for Flex, then back to >$20M by June 30) screams "metric still immature." Cantor says it’s got limited financial materiality today.
Bottom line: DAP (Duo Agent Platform) is a FY28 story. UBS flagging fiscal 2027 guidance as "increasingly conservative" matters — but at 3.7x CY27 revenue, the r/r is balanced, not a slam dunk.
Bull case: Seat growth reaccelerating, AI attach via DAP is real (pilot in Q4), new logos accelerating, and 86%+ gross margins with $1B revenue run rate. If the consumption model scales, GTLB trades like a platform multiple expansion story.
Bear case: Neutral consensus at $35 says everything — stock is pricing in the conservatism already. DAP is still a pilot, consumption run rate is tiny (~$20M annualized), and the customer cohort that got price-sensitive last quarter hasn’t fully recovered. Risk/reward is symmetrical until we see the next print.
Actionable? Not for a PM unless you have a three-month view on DAP checks accelerating. This is a hold / small add into a beat-and-raise quarter — but the $35 ceiling from four analysts suggests the easy money is gone.
VERDICT: Engagement anxiety has officially become the dominant narrative, and the setup into earnings is horrid. Two analyst notes hit this morning — neither outright bearish on ratings, but both leaning hard into concerns that the post-price-hike engagement fade is real. Stock at $73.37, near 52-week lows, down 22% YTD. This thing has broken its trend. The question is whether Q2 print (July 16) acts as a flush or a floor.
Multiple compression is already happening — KeyBanc cut its PT to $92 from $115 (Overweight maintained) citing "engagement concerns raising questions about long-term growth." They explicitly compared it to the 2022 trough. The saving grace? Last time, ad-tier and paid sharing were the levers. This time, they're betting on content/product diversification — partnerships like TF1 and live events (World Cup bid, more on that below).
Citizens reiterated Market Perform, focused on the World Cup rights chase. Netflix, Disney, and YouTube challenging Fox for U.S. broadcast rights to the 2030 and 2034 World Cup, with packages potentially $2B each. That's a real capital allocation debate — do they need live sports that badly, or is it just table stakes for global scale?
"The current situation reminds the firm of challenges Netflix faced in 2022." — KeyBanc analyst
That's actually bullish in disguise. 2022 was the nadir. They fixed it. New levers (live events, partnerships, content diversification) could aid "perceived content quality and support better monetization per hour." World Cup rights would be a massive engagement driver — but you're paying up front and hoping the ad model catches up. Bernstein still Outperform (PT lowered to $100) — they see subscriber growth pressure but think the World Cup cycle eventually helps.
Engagement data is real. Price increases are biting. Subscriber growth is slowing — Bernstein estimates -3M subs in FY2026. Options market pricing a 7.3% move post-earnings — that's elevated even by NFLX standards. Benchmark (Hold) notes "engagement appears to be weakening following recent price increases." KeyBanc's multiple compression (20x 2028E P/E) signals they think the re-rating is structural, not just cyclical. Citizens flags World Cup will "represent ripple effects for advertising and engagement" as it diverts attention and ad dollars. Translation: Q2 is going to look ugly, and Q3 might too.
We're heading into earnings with a stock that's already priced for disappointment. But the comp to 2022 cuts both ways — if management has another trick up its sleeve (big content slate, ad-tier acceleration, buyback), the setup could be a snapback. If Q2 print misses and guidance disappoints, sub-$70 is in play. Positioning is lean, but the narrative is poison right now. We'd wait to see the print, then look for the reaction — either the flush we need to get long, or the beat that catches everyone flat-footed.
Stock split is a non-event, but the dispersion in post-split PTs ($169–$235) tells you more about the tape than the split does. Rosenblatt mechanically dropped its target to $206 (from $825, factoring the 4-for-1) and kept Buy. No change to estimates, no change to thesis. Cantor Fitzgerald still at $725 pre-split (~$181 adjusted and unchanged), UBS bumped to $235 (bullish on AI), Stifel to $220, Morgan Stanley to $172, Barclays to $169. That’s a ~28% range on a $187 stock. The signal isn’t the split — it’s that the bull case (AI tailwinds, 75% gross margins, 23% rev growth) is still debated against a $191B market cap that already prices in a lot.
“The new price target represents only the arithmetic of the split with no change to the firm’s rating, dollar-based estimates, valuation methodology, or investment thesis.” — Rosenblatt
Bottom line: CRWD is a high-quality compounder with a wide moat, but the multiple is already rich. The split brings in retail flow (psychological, not fundamental). PMs should watch whether the post-split float increase drives any incremental selling from index rebalancers or options dealers. Fundamentals unchanged — but the rate of change in consensus PT revisions is slowing. Not a short, but not a slam-dunk long at these levels until the next catalyst (earnings, large deal win, or a macro derisking).
TD Cowen just ripped the PT to $215 from $160 (Buy maintained) on Q2 checks that sound like a beat-and-raise setup. 38 analysts have revised estimates up. The channel is fire: VARs are 15% over quota, seven-digit deals on FG-4000/5000 are standard, and eight-digit deals are on the table. Data center build-out for AI is the incremental tailwind.
"Several VARs have exceeded quarterly quotas by as much as 15%"
TD Cowen bumped Q2 billings to $2.23B (from $2.164B) and product rev to $675M (+33% YoY). Full-year rev now $7.854B vs consensus $7.806B. New PT of $215 implies 52x FY27 FCF (from 39x). That's a re-rate, not a margin of safety.
The bull case is straightforward: demand re-acceleration on AI infra, SASE/SECOps attach, and billing momentum. Bear case is the multiple. 61x P/E on $115B market cap leaves little room for error. HSBC downgraded to Reduce at $102 (valuation call). July 29 print is the next catalyst – stick to the narrative, not the multiple here.
Needham is sticking to its guns on SMTC after investor meetings, and they’re not alone. The stock is up 183% in the last year, trading at ~$136 with a $12.7B market cap, and the bull case is getting sharper: 800G/1.6T optical demand is running ahead of plan, CopperEdge ACC is ramping at the lead hyperscaler, and LoRa+ is seeing multi-protocol adoption. Needham keeps a $200 PT (50x FY29 EPS of $4.00), but the rest of the Street has been lifting targets into the $188-230 range post-Q1 print.
“Key growth drivers include better than expected 800G and 1.6T optical module shipments and share gains with 1.6T TIAs.”
The forward story is about duration. SMTC isn’t just riding the current cycle — they’re already sampling multi-wavelength DWDM lasers for CPO/NPO and TIA/driver arrays for NPO applications targeting 2028+. That’s the kind of pipeline that justifies the multiple if execution holds. Risk here is that the stock is pricing in a lot of perfection (50x forward earnings on a ’29 base), but the rate of change in optical demand and hyperscaler buildouts keeps the narrative intact. PMs should watch the CopperEdge ramp as the next quarterly tell — if that accelerates, the $200+ targets start looking conservative.
APH keeps printing. TD Cowen ups PT to $175 from $135, but sticks with Hold — which tells you the stock is already pricing in the AI boom. Revenue SURGED 54% LTM to $25.9B, driven by AI infrastructure. Street is racing higher too: Barclays $180 OW, BofA $185 Buy, Evercore $180 Outperform. Everyone sees the same tape.
"The firm’s updated financial model stands 7% above consensus estimates for 2026 and 15% above for 2027."
That’s the key — TD is already above consensus and still only Hold. Means either they think upside is capped, or they’re waiting for a better entry after the 62% run. Note the narrative shift: copper fears are dead, now it’s about CPU vs GPU ratios. Q2 prints July 29 — expectations are high. APH is the plumbing for AI, and nobody is turning off the tap. But Hold from a firm that’s 7-15% above consensus? That’s the compromise between “great business” and “not cheap enough.”
TD Cowen reiterates Buy / $1,600 target after investor meetings with CEO & CFO. Stock's already up 700% in the past year ($975 / $1.1T market cap). Thesis is simple: physical supply constraints persist beyond 2027, demand from hyperscalers / enterprises / automakers is so strong that even customers with supply agreements can't fully cover volume. Nearly 50% of rev is locked into those agreements long-term.
Near-term pricing gives the EPS story real teeth. Field work shows DDR ASPs up >15% in Q3 calendar 2026, then mid-single digit growth thru Q1 2027. That implies Street's $160 CY27 EPS estimate is too low. 27 analysts have revised estimates up — but the stock's still $975? That's a ~6x forward P/E. You don't pay 6x for 15% sequential ASP growth and a structural supply deficit.
"Recent field work indicates DDR average selling prices will likely grow more than 15% in the third calendar quarter, followed by mid-single digit growth in the fourth quarter of 2026 and first two quarters of 2027. This implies upside to the Street’s $160 earnings per share estimate for calendar year 2027."
The bear case (not from this note) is Samsung's earnings forecast hit the sector. That's a sentiment thing, not a MU-specific fundamental breakdown. If you're long, you're betting the supply/demand math for HBM and DDR5 overrides short-term Samsung noise. Given the CAPEX trajectory ($250bn US by 2035, Clay facility ahead of schedule), MU is playing offense on AI memory. Constraint is the edge — not end-market weakness.
Taking a fresh look at BELFB after two Street initiations this week. Citi starts Buy, $325 PT (19% upside). JPMorgan more aggressive at Overweight, $370 PT (~30% upside). Both bulls are buying the transformation story — a decentralized components supplier that's now an AI/defense infrastructure play.
"Bel Fuse has shifted from a decentralized, product-oriented organization into a power, connectivity, and defense electronics supplier." — Citi's Asiya Merchant
The narrative is clean: they've pivoted into the right end markets (aerospace, defense, AI infra) and investors are paying up for it. Stock is +60% YTD after a 170% return last year. The 63x trailing P/E is eye-popping but the Street looks through it — forward multiples are 27x P/E and 21x EV/EBITDA.
Bulls see a rerating story with room to run. The margin improvement thesis is real — profitability focus + end market refinement + M&A execution. JPMorgan's $370 target implies the stock hasn't fully priced in the structural shift yet.
Bears point to the valuation. 63x trailing earnings is priced for perfection in a company that still makes connectors and power supplies. Not sure we can read too much into that multiple given the recent earnings trajectory, but it's a bogey for any hiccup in the AI/defense spend cycle.
Net net: fresh analyst coverage creates a catalyst for the stock to retest highs. The r/r depends on whether you believe the transformation is fully discounted at 21x EBITDA. We'd let the momentum play out but wouldn't chase on a 170% year.
Morgan Stanley upgrades KEYS to Overweight, PT to $400 from $350. The call is pure AI infrastructure capex spillover — but MS is framing it as a structural shift in test intensity, not a cyclical pop. They see the concurrency of Ethernet vs Infiniband, 800G ramp, 1.6T R&D, and early 3.2T planning creating a "longer growth runway" than the market gives T&M names.
"Faster innovation cadence and greater system complexity should support a longer growth runway than investors typically assign to test and measurement companies."
KEYS trades $322 (still a $55B mkt cap, +97% in the year) — not cheap, but MS thinks the PT comes via estimate revisions as "testing density" and incremental margins improve. AI revenue is mid-teens of total, so it's not pure AI — but the architecture debate (Ethernet vs Infiniband, etc.) won't resolve for years, which means KEYS gets to sell into multiple winners. Recent acquisitions (VPIphotonics, new cybersecurity test platform) add optionality. Feels like a rate-of-change story: not just demand, but duration.
Verdict: SNDK keeps printing. Evercore ISI joins the parade, hiking PT to $3,100 (stock at $1,915.92) on the durability of those New Business Model agreements. The thesis is simple: supply/demand imbalance through 2027, pricing power intact, and now you have $62B of minimum committed revenue across five deals with >$11B in financial guarantees and prepayments. That’s not a story – that’s a cash flow bridge.
Evercore models FY27 revs of $47.8B and EPS of $212.78, valuing the stock at ~15x that number. The kicker: over one-third of FY27 bits will be tied to these secured contracts, and those deals carry gross margins above 80%. That’s the structural upgrade here – the business is shifting away from spot-market volatility toward locked-in, high-margin revenue.
Bernstein ($3,000) and Susquehanna ($3,250) already flagged the downside protection from the financial commitments. Evercore is just quantifying the scale: $62B in committed revenue is a massive floor. The 4,057% return over the past year is eye-popping, but the forward multiple (mid-teens) still leaves room if execution holds. The risk? Consumer demand destruction, which so far has been “less severe than anticipated” per Bernstein. Not a clean setup, but the r/r tilts bull.
“Evercore projects over one-third of SanDisk’s fiscal 2027 bits will be tied to these agreements at gross margins above 80%.”
That’s the line that matters. If those margins hold, SNDK is a cash machine. Keep it on the radar – especially on any DRAM/NAND price pullback.
Verdict: BUY-SIDE VOTE OF CONFIDENCE. JMP/Citizens reiterates Market Outperform with $550 PT (MSFT at ~$424 – plenty of runway). Thesis: Microsoft’s AI transformation is about enterprise control, not just automation. The 4,800 role cuts (2.1% of workforce) aren’t being replaced by AI — but the new Microsoft Frontier Company (6,000 experts, $2.5B) is a direct bet on helping customers design, deploy, and own AI systems.
“Enterprises increasingly want control over their data, models, agents, tools, and governance.”
That’s the real narrative shift. Not “AI takes your job” but “AI becomes your accountable co-pilot.” The Frontier company is basically a 6,000-person consulting/engineering army for large-scale AI transformation. Feels like a sleeper catalyst if enterprise adoption accelerates.
One to watch. MSFT at 30x fwd earnings with $2.86T market cap isn’t screaming “cheap” — but the rate of change in AI revenue (and this organizational pivot) is underappreciated. $550 PT implies ~30% upside. Not a stretch if the Frontier unit starts printing results.
Verdict: TD Cowen sees NET as a structural AI/security compounder, raising PT to $300 from $265 ahead of the July 30 print. The bull case rests on revenue growth re-accelerating toward ~30% (last twelve months was 31.6%, gross margins 73% — that’s elite SaaS unit economics). Shaul Eyal is leaning on Workers AI, larger deal flow, and Pool-of-Funds transactions as durable levers. Stock at $268.40, within a stone’s throw of its $280 52-week high — market is already pricing some of the optimism.
The note’s strongest point is the AI-as-security catalyst narrative from their June 6 report “Road Ahead: Autonomous Defense Meets Autonomous Threats.” That’s the kind of framing that makes PMs pay attention — not just another AI tailwind story, but a specific angle where Cloudflare’s edge (network-level visibility) becomes a defensible moat.
“AI is creating security opportunities for the company” — TD Cowen, referencing their thematic piece on autonomous defense vs. autonomous threats.
What else is in the mix: Scotiabank upgraded to Sector Outperform with a $300 PT; OpenAI collaboration on search indexing; beehiiv AI crawl control partnership. All reinforce the narrative that Workers is becoming an AI infra layer, not just a CDN. Earnings are July 30 — this is a positioning play into that print.
Qualys is still not cheap enough to buy the story. TD Cowen just ripped its price target from $90 to $145 (+61%!) — but the stock trades at $152 and they kept the Hold. That tells you everything. The firm sees Q2 current billings growing 9% YoY, in line with Street, and adj. EPS of $1.91 (14% growth, beating the $1.79 consensus) on lower opex growth. Gross margins hum at 83%, balance sheet pristine — more cash than debt. So what's the problem?
Competitive rivalry is the bogey. TD Cowen explicitly flags "the level of competitive rivalry in the vulnerability management space" and calls out the emergence of new AI tools as adding "uncertainty about the potential size of the vulnerability management TAM." That's a structural headwind, not a quarter-to-quarter noise.
"We remain cautious about the level of competitive rivalry in the vulnerability management space. The emergence of new artificial intelligence tools adds uncertainty about the potential size of the vulnerability management total addressable market."
The analyst community is a mess of conflicting signals. JPMorgan upgraded from Underweight to Neutral and hiked PT to $139 ($87 prior). RBC Capital raised to $90, Scotch-bank cut to $100 from $135. Net-net: PTs range from $90 to $145, and the stock already trades at $152. That's a premium to every published target. The street is chasing the rally, not leading it.
Positives: FedRAMP High Authorization with DEA sponsorship opens federal flow-through. Management noted customer interest from Anthropic Claude Mythos and OpenAI GPT-5.4-Cyber partnerships. But this is a show-me story — the AI angle hasn't materialized into a measurable TAM expansion yet. PMs: wait for a pullback closer to $130-135 before committing new capital. The r/r at $152 is skewed bearish given the competitive overhang.
Verdict: Jefferies goes full Buy on the agentic commerce thesis. Stock down 27% in six months despite 32% rev growth — that’s the setup. PT to $160 from $140, implying ~30% upside from here ($122.54). Not the only bull: Stifel, Citizens, Piper all at $150, UBS stuck at Neutral $130. The collective story is that SHOP is becoming the rails for AI-intermediated commerce, not just a checkout button.
The catalyst is the August 2026 partner commission overhaul — capping earnouts and tying them to value created. Forces partners to chase bigger logos and cross-sell B2B, POS, Components instead of clipping coupons. Long-term unit economics improve.
"Positioned to become the infrastructure layer for agentic commerce and the agent enablement toolkit for merchants."
Manus integration (conversational store management) adds another angle. Rate of change on AI monetization is accelerating. Risk: the stock has been dead money for six months while fundamentals ripped — sometimes that’s a shakeout, sometimes it’s a value trap. Betting on the former.
Take: Citizens still bulls up the tape — $515 PT stands, KeyBanc just raised to $445 — and the real driver is the AI infra upgrade cycle that’s barely started. The State of AI infrastructure report is the catalyst: 83% of orgs need upgrades just to run production-grade agentic AI, and 29% require major core system overhauls. That’s a multi-year hyperscaler demand signal, not a one-quarter bump. Enterprise AI spending hasn’t proliferated yet (the infrastructure cycle is early), so GOOGL’s Cloud and Search revenue running above 20% growth through 2028 (per KeyBanc) is still the bull case anchor.
“Enterprise AI spending has yet to fully proliferate, given that the infrastructure upgrade cycle remains early.”
Stock’s up 98.8% in the last year, P/E 27.2x — not cheap, but the rate of change argument hinges on that infra cycle widening the TAM, not compressing it. Being long here is a bet that CapEx fear gives way to real revenue acceleration.
Evercore ISI keeps Outperform / $365 PT despite the OpenAI lawsuit — they see no fundamental damage. UBS holds at Neutral / $296, citing mixed survey data (US iPhone intent up, China soft). The suit itself is noise for now: Apple’s hardware moat isn’t broken by 400 ex-employees, and the Broadcom silicon deal ($30B+) is the real signal.
“The complaint names two former Apple executives now at OpenAI, but we don’t see this altering Apple’s competitive position or its partnership with OpenAI — the Street will shrug unless discovery reveals something worse.”
Bottom line: lawsuit is a headline risk, not a thesis breaker. UBS’s caution on China demand is the more actionable friction point.
Verdict: Beat was real, but valuation already pricing it in. Jefferies bumps PT to $400 (from $375) but keeps Hold — stock trades $407, so they're calling it overvalued. The Q2 volume print was a monster: 480k deliveries vs 406k consensus (18% beat). That’s enough to lift Jefferies' EBIT estimate to $1.45B (5.1% margin) and FY26 EBIT +4% to $6.2B. But they still see $7.5B FCF outflow on $23B capex. Not a screaming buy at 1.5x market cap.
"The stock currently appears overvalued" — Jefferies, post-beat PT raise.
Rest of the Street is split: JPMorgan Neutral $475, RBC $500 (SpaceX acquisition scenario), Morgan Stanley Equalweight $415. No one’s pounding the table. The volume beat is a positive rate-of-change signal, but the narrative is still "great execution, insane multiple." Watch the earnings print in 9 days — margin details will matter more than the headline delivery number.
TSM — June revenue NT$442.68B ($13.79B), +67.9% YoY, +6.2% MoM, shattering 4-year June seasonality (avg -11%). Q2 revenue $39.63B at top end of $39-40.2B guidance — 4th consecutive ATH month. Hard demand confirmation, beat accelerating. 1.4nm fab pulled ahead to April 2027 completion vs prior 2028. This is a capex acceleration signal. 2026 capex plan $52-56B plus $3.1B for two new advanced packaging plants. The structural density gap vs Intel widening to 50-60%. Pricing power across the stack, including mature-node hikes in Q4 2026. Multi-year capacity build with long-term conviction.
NVDA — Pricing density premium now near ASIC parity on a per-FLOP basis. Neutralizes the headline TCO argument for custom silicon — if NVDA margins were 0, labs could only offer tokens ~50-60% cheaper, not an order of magnitude. Vera Rubin NVL72 rack delivers 200 AI petaFLOPs, assembles in one minute, liquid-cooled. Supply chain confirms Rubin production release late July, CoWoS cuts offset by 150% Rubin ramp. Labs diversifying but absolute NVDA spend increasing. PEG ratio sub 0.3x, hedge funds bought US semis at fastest pace in 3.5 years. Valuation not pricing current demand acceleration.
INTC — UBS $121 PT rests on revenue model ($70B next year, $95B by 2030) materially below realistic trajectory — consensus embeds no AI accelerator volume. Realistic path is $150B. Investing €5B in Ireland to upgrade existing fab for Xeon 6 and Intel 3 — capacity maintenance, not growth. Density gap vs TSMC widening to 50-60%. Structural disadvantage accelerating.
AMD — Anthropic potentially becoming AMD's largest AI customer validates AI revenue path. Major milestone if confirmed — signals lab urgency to reduce NVDA dependence. But vLLM performance gap vs NVIDIA remains material on certain models. Software ecosystem gap is the binding constraint.
ORCL — Oracle Cloud portrayed as one of the world's biggest hyperscalers with alleged RPO over half a trillion dollars. Reinforces status as credible third hyperscaler behind AMZN, MSFT, GOOGL. The RPO number is massive if even partly real.
ASML — EUV shipment forecasts lifted to 66/95/109 for 2026/27/28 as supply bottlenecks ease against strong memory and logic demand. This implies a multi-year capacity build cycle accelerating. Direct beneficiary of TSMC and Samsung capex pull-forward.
AVGO — Leading Scale-Up Ethernet (SUE) as open alternative to NVLink. Also involved in CPO switch platforms. Positions Broadcom in the networking upgrade cycle as AI clusters scale. The open networking thesis gaining traction.
MRVL — Positioned in CPO roadmap, ZR optics, and 1.6T bottleneck solutions. Expert calls indicate active diligence on data center optical interconnects. The 1.6T upgrade cycle is the next big networking catalyst.
CRDO — Part of CPO roadmap discussion, though specific product positioning unclear. Mentioned alongside AVGO and MRVL in expert calls. Early stage, but the CPO theme pulls all optics names up.
ALAB — Positioning for CXL controllers and switches to address memory scarcity in AI servers. MSFT, META, GOOGL likely adopters. CXL gaining relevance as memory bandwidth becomes a bottleneck. This is a thematic tie to the disaggregated compute trend.
NVTS — Pure-play WBG leader, earliest mover in HVDC GaN for AI data centers. GaNFast power ICs and high-voltage SiC (GeneSiC) target the 800V DC migration. Small-cap high-beta — highest pure exposure to the data center power theme.
IFX — Diversified power semi giant, earliest mover in SiC for HVDC. Leader in SiC (CoolSiC) with strong GaN (CoolGaN). Most 'ready' incumbent for 800V DC ecosystems with qualified parts and modeling support. Structural beneficiary of AI power architecture shift.
MPWR — Fabless specialist in highly integrated power management ICs (DC-DC converters, voltage regulators) that sit within the server. Higher margins, less pure WBG exposure. Beneficiary of higher server power draw but not as directly tied to the DC architecture shift.
WOLF — Making a high-risk bet on next-generation high-voltage SiC positioned after the grid for AI data centers. Technology not yet widely adopted. Has been overwhelmed by low-cost Chinese EV SiC competition. High risk/reward but unclear catalyst.
STM — Currently an average player in HVDC as it didn't anticipate the opportunity as early as IFX and NVTS. Sources wafers from Innoscience for GaN HVDC. Playing catch-up in the power semi stack.
ON — Currently an average player in HVDC as SiC is getting killed by Chinese peers with limited differentiation. Pushing high-voltage GaN (vertical GaN) story in preparation for next phase of HVDC adoption. Need to see product traction.
ASX — ASE Technology Q2 revenue NT$191.06B ($5.95B), +26.7% YoY, a record high driven by AI-related sales. June revenue rose 32.9% to NT$65.78B, its 2nd best month ever. Demand accelerating at packaging level. Direct read-through for TSMC and NVDA supply chain.
SPCX — COLOSSUS clusters achieve build speeds 6-8x faster than industry benchmark. 1GW of compute online as of 1Q26. Anthropic paying $15B annually for 300MW+ — near-term revenue validation. Market cap fallen from ~$2.95T peak to ~$1.82T — post-listing profit-taking, not fundamental deterioration. At 112x adjusted estimates, Bernstein sees Chinese launch threat but no PT change.
AMZN — Part of the $75B bond issuance wave from NVDA, SPCX, and AMZN funding AI infrastructure. Confirms hyperscalers are using capital markets to fund expansion. No new fundamental data but reinforces capex trajectory.
AMAT — #1 in DRAM WFE share with five inflections driving growth: EUV, 4F², 3D DRAM. Plus >50% leading-edge logic growth. Multiple cyclical tailwinds — a clean way to play semi equipment recovery without single-customer risk.
SKHY — 2Q26 operating profit miss ~8% vs consensus due to LTA accounting effect, not demand. Blended ASP growth estimate lowered to +28.9% QoQ (previous +50%) but will return to ~10% in 3Q26 as HBM4 mass production begins. ADR listing triggered record domestic retail extraction — stock plunged 15-17% in Seoul, KOSPI circuit breaker. Technical supply shock, not fundamental. HBM4 mass production set for 3Q26 — leadership intact.
SEC — Samsung recommended top-pick by KIS KR on pricing leverage in conventional DRAM/NAND and leadership in HBM4/4e. Superior pricing leverage in negotiations. Imminent employee compensation buyback and biggest ever shareholder return (special dividend end-FY26 plus new 3-year cycle). Near-term catalyst.
PLTR — Mentioned as one of the select software names seeing capital rotation amid the semiconductor sell-off. No specific fundamental catalyst. Just a rotation trade.
VLO — Refining sector seeing heavy chatter as Brent surges above $80 and Strait of Hormuz blockade tightens supply. Refining structurally tighter, higher mid-cycle, lower terminal multiple. Beneficiary of geopolitical oil supply disruption.
MPC — Similar to VLO — beneficiary of tighter refining conditions due to geopolitical tensions. Same macro driver.
PSX — Phillips 66 mentioned in refining chatter as beneficiary of oil supply disruption. Same theme.
DINO — HF Sinclair mentioned in the context of US refining stocks seeing heavy chatter. Refining trade is a crowded beta play on oil supply risk.
TMDX — TransMedics +5% on TD Cowen Buy reiteration with $120 PT. 5% YoY growth in US transplant volumes. Small uptick but signals continued execution in organ transplant logistics.
BIIB — Biogen upgraded to Buy at Truist on Alzheimer's/pipeline optimism. Laggard in the biotech space; upgrade is a contrarian bet on Leqembi ramp.
AZN — AstraZeneca downgraded at HSBC on 'tough path ahead'. No specifics but reflects competitive pressure in oncology.
ALNY — Trading action noted as 'truth prevailing in the long run'. No specific data point. Just a hold.
TREX — Q2 net sales $418M vs $398M est, FY sales guidance $1.215-1.250B. New SBP distribution agreement may indicate channel load-in. Decking demand holding up — housing macro still supportive.
WIX — Valued at 1x ARR despite $2.1BN revenue. CEO argues moat is enterprise trust and complex workflows. AI coding disruption concerns weigh — the market is pricing in platform risk.
HOOD — Seeking $400M-$500M in ABS offering. Capital raise to fund growth. Not a fundamental catalyst but shows management is funding crypto/equities expansion.
OWL — Blue Owl Capital owns 80% of Meta Louisiana data center project through SPV. Earlier in 2026, froze withdrawals from private credit fund. This creates counterparty risk if AI revenue doesn't materialize. The SPV structure concentrates risk.
ETR — Entergy Louisiana building 10 new gas-fired power plants to support Meta's 5GW data center campus. Direct beneficiary of AI infrastructure buildout. Regulated utility with AI capex visibility.
WULF — TeraWulf signed a 20-year, $19B lease with Anthropic covering 401MW of critical IT load. Landmark deal validating data center infrastructure demand. Converts bitcoin mining capacity to AI compute — smart pivot.
APO — Apollo proposed £5.7B takeover of easyJet at 111% premium to price 2 months ago. Shows private equity appetite for travel recovery. Not directly relevant to tech but signals capital rotation.
PARA — 12 states including California suing to block Paramount-WBD $110B merger. Regulatory risk increasing. Deal in jeopardy — headline risk only.
WBD — Same as PARA — states suing to block merger. Regulatory overhang.
JPM — Reports earnings this week. Trading revenue could beat if macro volatility drove activity. Read-through for rates/credit chain. Not a TMT name but macro context for book beta.
C — Citigroup also reporting, similar macro vol benefit expected. Same read-through.
WFC — Wells Fargo earnings this week — could see trading revenue lift. Not a TMT name, just macro.
BAC — Bank of America reports this week. Same.
GS — Goldman Sachs earnings this week. Same.